{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:57:40Z","timestamp":1791507460486,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rare paediatric central nervous system (CNS) tumours comprise a biologically-heterogeneous group of low-incidence diseases that present significant challenges to both therapeutic development and clinical research, limiting the availability of high-quality evidence to guide clinical care. The UK3CR Children\u2019s Cancer Research Group (CRG) CNS Tumours Subgroup convened a multidisciplinary workshop to identify research priorities and establish a strategic framework for advancing clinical trials in this setting. Four high-priority tumour groups\u2014craniopharyngioma, choroid plexus carcinoma (CPC), very high-risk medulloblastoma (VHR-MB), and rare embryonal and sarcomatous tumours (REST), including embryonal tumour with multilayered rosettes (ETMR)\u2014were evaluated. Key outcomes included the feasibility of a UK-led craniopharyngioma trial, the need for enhanced national CPC data collection, and support for European early-phase platform trials in VHR-MB. REST highlighted transnational regulatory complexity requiring coordinated registries and parallel trial models. Cross-cutting barriers included regulatory discordance, contracting delays, fragmented funding, pharmacovigilance differences, data-sharing constraints, and interoperable infrastructures. The workshop emphasised innovative methodologies, including Bayesian\/adaptive designs, platform trials, and external control arms, to maximise efficiency in small populations, alongside strengthened patient involvement and international collaboration. Collectively, these findings define a collaborative and internationally-aligned strategic roadmap to accelerate clinical research and improve outcomes in rare paediatric CNS tumours.<\/jats:p>","DOI":"10.1038\/s41416-026-03589-6","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:43:11Z","timestamp":1787398991000},"page":"1183-1193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus"],"prefix":"10.1038","volume":"135","author":[{"given":"Jenny","family":"Adamski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Apps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Depani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Pizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thankamma","family":"Ajithkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim S.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Carceller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia V.","family":"Cockle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Dineen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Douglas\u2011Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Gains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Paul","family":"Kilday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-7276","authenticated-orcid":false,"given":"Juan-Pedro","family":"Martinez\u2011Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Ritzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-9807","authenticated-orcid":false,"given":"Darren","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-5070","authenticated-orcid":false,"given":"Allan","family":"Hackshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-9972","authenticated-orcid":false,"given":"G. A. Amos","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-2184","authenticated-orcid":false,"given":"Steven C.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"3589_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103003","volume":"140","author":"S Stacchiotti","year":"2025","unstructured":"Stacchiotti S, Pantziarka P, Leonard H, Voltz C, Abatedaga L, Bouche G, et al. How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers. Cancer Treat Rev. 2025;140:103003.","journal-title":"Cancer Treat Rev"},{"key":"3589_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28993","volume":"68","author":"A Ferrari","year":"2021","unstructured":"Ferrari A, Schneider DT, Bisogno G, Reguerre Y, Godzinski J, Bien E, et al. Facing the challenges of very rare tumors of pediatric age: The European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) background, goals, and achievements. Pediatr Blood Cancer. 2021;68:e28993.","journal-title":"Pediatr Blood Cancer"},{"key":"3589_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1470-2045(12)70570-3","volume":"14","author":"N Keat","year":"2013","unstructured":"Keat N, Law K, Seymour M, Welch J, Trimble T, Lascombe D, et al. International rare cancers initiative. Lancet Oncol. 2013;14:109\u201310.","journal-title":"Lancet Oncol"},{"key":"3589_CR4","unstructured":"NHS England. National Disease Registration Service: Cancer statistics report 2021. https:\/\/digital.nhs.uk\/ndrs\/data\/data-outputs\/cancer-publications-and-tools\/ctya-uk-cancer-statistics-report-2021\/appendix-and-downloads#appendix-b-cancer-incidence-and-survival-tables. Accessed 01 May 2026."},{"key":"3589_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00401-020-02182-2","volume":"140","author":"S Lambo","year":"2020","unstructured":"Lambo S, von Hoff K, Korshunov A, Pfister SM, Kool M. ETMR: a tumor entity in its infancy. Acta Neuropathol. 2020;140:249\u201366.","journal-title":"Acta Neuropathol"},{"key":"3589_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/neuonc\/noae178","volume":"27","author":"EC Schwalbe","year":"2025","unstructured":"Schwalbe EC, Lindsey JC, Danilenko M, Hill RM, Crosier S, Ryan SL, et al. Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study. Neuro Oncol. 2025;27:222\u201336.","journal-title":"Neuro Oncol"},{"key":"3589_CR7","doi-asserted-by":"publisher","first-page":"1167082","DOI":"10.3389\/fonc.2023.1167082","volume":"13","author":"C Jones","year":"2023","unstructured":"Jones C, Straathof K, Fouladi M, Hargrave D, Prados M, Resnick A, et al. Evaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks. Front Oncol. 2023;13:1167082.","journal-title":"Front Oncol"},{"key":"3589_CR8","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1200\/JCO.22.00033","volume":"40","author":"B De Wilde","year":"2022","unstructured":"De Wilde B, Barry E, Fox E, Karres D, Kieran M, Manlay J, et al. The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions. J Clin Oncol. 2022;40:3456.","journal-title":"J Clin Oncol"},{"key":"3589_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-100051","volume":"45","author":"V Subbiah","year":"2025","unstructured":"Subbiah V, Othus M, Palma J, Cuglievan B, Kurzrock R. Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras. Am Soc Clin Oncol Educ Book. 2025;45:e100051.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3589_CR10","doi-asserted-by":"crossref","unstructured":"Yuan Y, Lee JJ, Hilsenbeck SG. Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precis Oncol. 2019.","DOI":"10.1200\/PO.19.00032"},{"key":"3589_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0638-z","volume":"19","author":"GM Wheeler","year":"2019","unstructured":"Wheeler GM, Mander AP, Bedding A, Brock K, Cornelius V, Grieve AP, et al. How to design a dose-finding study using the continual reassessment method. BMC Med Res Methodol. 2019;19:18.","journal-title":"BMC Med Res Methodol"},{"key":"3589_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020;382:1430\u201342.","journal-title":"N Engl J Med"},{"key":"3589_CR13","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1161\/STROKEAHA.106.474080","volume":"38","author":"C Optimising Analysis of Stroke Trial","year":"2007","unstructured":"Optimising Analysis of Stroke Trials C, Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke. 2007;38:1911\u20135.","journal-title":"Stroke"},{"key":"3589_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.urolonc.2025.08.023","volume":"44","author":"Z Cheng","year":"2026","unstructured":"Cheng Z, Campbell T, Hunt TC, Li A, Ceraolo C, Doersch K, et al. Evaluation of event-free survival as a surrogate for overall survival in genitourinary rhabdomyosarcoma. Urol Oncol. 2026;44:49\u201354.","journal-title":"Urol Oncol"},{"key":"3589_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00381-012-1926-2","volume":"29","author":"AJ Clark","year":"2013","unstructured":"Clark AJ, Cage TA, Aranda D, Parsa AT, Sun PP, Auguste KI, et al. A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma. Childs Nerv Syst. 2013;29:231\u20138.","journal-title":"Childs Nerv Syst"},{"key":"3589_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrendo.2010.168","volume":"6","author":"HL Muller","year":"2010","unstructured":"Muller HL. Childhood craniopharyngioma-current concepts in diagnosis, therapy and follow-up. Nat Rev Endocrinol. 2010;6:609\u201318.","journal-title":"Nat Rev Endocrinol"},{"key":"3589_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1530\/EJE-16-0812","volume":"176","author":"TSE Tan","year":"2017","unstructured":"Tan TSE, Patel L, Gopal-Kothandapani JS, Ehtisham S, Ikazoboh EC, Hayward R, et al. The neuroendocrine sequelae of paediatric craniopharyngioma: a 40-year meta-data analysis of 185 cases from three UK centres. Eur J Endocrinol. 2017;176:359\u201369.","journal-title":"Eur J Endocrinol"},{"key":"3589_CR18","doi-asserted-by":"crossref","unstructured":"Yamaki VN, Sidpra J, Peres BS, Lind V, Quianga CDA, da Costa Borsatto GJ, et al. Long-term outcomes of paediatric craniopharyngiomas: a comparison of two large international series. Childs Nerv Syst. 2026;42.","DOI":"10.1007\/s00381-026-07154-7"},{"key":"3589_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","volume":"135","author":"JR Apps","year":"2018","unstructured":"Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target. Acta Neuropathol. 2018;135:757\u201377.","journal-title":"Acta Neuropathol"},{"key":"3589_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s40478-024-01838-4","volume":"12","author":"JR Apps","year":"2024","unstructured":"Apps JR, Gonzalez-Meljem JM, Guiho R, Pickles JC, Prince E, Schwalbe E, et al. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression. Acta Neuropathol Commun. 2024;12:127.","journal-title":"Acta Neuropathol Commun"},{"key":"3589_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/nan.12613","volume":"46","author":"JR Apps","year":"2020","unstructured":"Apps JR, Stache C, Gonzalez-Meljem JM, Gutteridge A, Chalker J, Jacques TS, et al. CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma. Neuropathol Appl Neurobiol. 2020;46:510\u20134.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3589_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jnen\/nlx061","volume":"76","author":"AM Donson","year":"2017","unstructured":"Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, et al. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. J Neuropathol Exp Neurol. 2017;76:779\u201388.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3589_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2025.102051","volume":"39","author":"JM Gonzalez-Meljem","year":"2025","unstructured":"Gonzalez-Meljem JM, Cao L, Apps JR, Martinez-Barbera JP. Decoding craniopharyngioma: From mechanisms to therapy. Best Pract Res Clin Endocrinol Metab. 2025;39:102051.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3589_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/neuonc\/noac221","volume":"25","author":"LM Hoffman","year":"2023","unstructured":"Hoffman LM, Jaimes C, Mankad K, Mirsky DM, Tamrazi B, Tinkle CL, et al. Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group. Neuro Oncol. 2023;25:224\u201333.","journal-title":"Neuro Oncol"},{"key":"3589_CR25","doi-asserted-by":"publisher","first-page":"124050","DOI":"10.1016\/j.wneu.2025.124050","volume":"198","author":"I Mohammadzadeh","year":"2025","unstructured":"Mohammadzadeh I, Hajikarimloo B, Niroomand B, Faizi N, Faizi N, Habibi MA, et al. Artificial Intelligence-Based Radiomic Model in Craniopharyngiomas: A Systematic Review and Meta-Analysis on Diagnosis, Segmentation, and Classification. World Neurosurg. 2025;198:124050.","journal-title":"World Neurosurg"},{"key":"3589_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","volume":"12","author":"CL Roth","year":"2024","unstructured":"Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12:380\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3589_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.887544","volume":"13","author":"P Leblond","year":"2022","unstructured":"Leblond P, Massimino M, English M, Ritzmann TA, Gandola L, Calaminus G, et al. Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol. Front Neurol. 2022;13:887544.","journal-title":"Front Neurol"},{"key":"3589_CR28","doi-asserted-by":"crossref","unstructured":"Bahar M, Dhir A, Kordes U, Wolff J. PTCT-01: Intercontinental multidisciplinary data collection and treatment optimization study for patients with choroid plexus tumors. Neurooncology. 2015;17.","DOI":"10.1093\/neuonc\/nov229.01"},{"key":"3589_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11060-021-03942-0","volume":"156","author":"JE Wolff","year":"2022","unstructured":"Wolff JE, Van Gool SW, Kutluk T, Diez B, Kebudi R, Timmermann B, et al. Final results of the Choroid Plexus Tumor study CPT-SIOP-2000. J Neurooncol. 2022;156:599\u2013613.","journal-title":"J Neurooncol"},{"key":"3589_CR30","volume":"6","author":"M Yankelevich","year":"2024","unstructured":"Yankelevich M, Zaky W, Lafay-Cousin L, Osorio D, Adamski J, Kordes U, et al. Marrow-ablative consolidation chemotherapy and molecular targeted therapy delivered in a risk-adapted manner for newly diagnosed children with choroid plexus carcinoma: A work in progress. Neurooncol Adv. 2024;6:vdae109.","journal-title":"Neurooncol Adv"},{"key":"3589_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2024.100205","volume":"5","author":"S Bailey","year":"2025","unstructured":"Bailey S, Jacobs S, Kourti M, Massimino M, Andre N, Doz F, et al. Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network. EJC Paediatric Oncology. 2025;5:100205.","journal-title":"EJC Paediatric Oncology"},{"key":"3589_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","volume":"5","author":"PA Northcott","year":"2019","unstructured":"Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, et al. Medulloblastoma. Nat Rev Dis Primers. 2019;5:11.","journal-title":"Nat Rev Dis Primers"},{"key":"3589_CR33","doi-asserted-by":"crossref","unstructured":"Bailey S, Andre N, Gandola L, Massimino M, Wheatley K, Gates S, et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers.2022;14.","DOI":"10.3390\/cancers14020374"},{"key":"3589_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/noab178","volume":"24","author":"S Richardson","year":"2022","unstructured":"Richardson S, Hill RM, Kui C, Lindsey JC, Grabovksa Y, Keeling C, et al. Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro Oncol. 2022;24:153\u201365.","journal-title":"Neuro Oncol"},{"key":"3589_CR35","unstructured":"Equihua CM, Baxter JS, Molenaar JJ, Areso I, Anderson J, Andre N, et al. Paediatric bespoke therapeutic development workshop on medulloblastoma. British Journal of Cancer, In Press. 2026."},{"key":"3589_CR36","doi-asserted-by":"crossref","unstructured":"Endersby R, Whitehouse J, Pribnow A, Kuchibhotla M, Hii H, Carline B, et al. Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Sci Transl Med. 2021;13.","DOI":"10.1126\/scitranslmed.aba7401"},{"key":"3589_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ccell.2014.11.002","volume":"27","author":"RM Hill","year":"2015","unstructured":"Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 2015;27:72\u201384.","journal-title":"Cancer Cell"},{"key":"3589_CR38","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1093\/neuonc\/noaf132","volume":"27","author":"C Mazewski","year":"2025","unstructured":"Mazewski C, Leary SES, Kang G, Li BK, Kellie S, Hayes L, et al. Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children\u2019s Oncology Group. Neuro Oncol. 2025;27:2726\u201337.","journal-title":"Neuro Oncol"},{"key":"3589_CR39","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","volume":"39","author":"APY Liu","year":"2021","unstructured":"Liu APY, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, et al. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021;39:1519\u201330 e4.","journal-title":"Cancer Cell"},{"key":"3589_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2022.104660","volume":"66","author":"J Gojo","year":"2023","unstructured":"Gojo J, Kjaersgaard M, Zezschwitz BV, Capper D, Tietze A, Kool M, et al. Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions. Eur J Med Genet. 2023;66:104660.","journal-title":"Eur J Med Genet"},{"key":"3589_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2025.100311","volume":"6","author":"JR Apps","year":"2025","unstructured":"Apps JR, Goddard J, Sahmoud S, Green K, Hedge K, Keeling C, et al. Multicentre evaluation of the management of children with high risk medulloblastoma: Real world performance of the SJMB03 and COG-99701 protocols. EJC Paediatric Oncology. 2025;6:100311.","journal-title":"EJC Paediatric Oncology"},{"key":"3589_CR42","doi-asserted-by":"crossref","unstructured":"Richardson S, Hicks D, Gough M, Butler ER, Thompson D, Castle J, et al. Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study. eClinicalMedicine. 2026;103913.","DOI":"10.1016\/j.eclinm.2026.103913"},{"key":"3589_CR43","doi-asserted-by":"crossref","unstructured":"Richardson S, Hicks D, Gough M, Butler ER, Thompson D, Castle J, et al. Integrated biomarker and treatment correlates of prognosis in infant non-WNT\/non-SHH medulloblastoma: a multinational retrospective cohort study. Lancet Child Adolesc Health. 2026.","DOI":"10.1016\/S2352-4642(26)00067-2"},{"key":"3589_CR44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1158\/2159-8290.CD-24-0916","volume":"15","author":"SL George","year":"2025","unstructured":"George SL, Lynn C, Stankunaite R, Hughes D, Sauer CM, Chalker J, et al. Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States. Cancer Discov. 2025;15:717\u201332.","journal-title":"Cancer Discov"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03589-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:01:50Z","timestamp":1791270110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03589-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10,20]]}},"alternative-id":["3589"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03589-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FC declares a consulting role for Ipsen. DH declares clinical trial funding from Alexion\/ AstraZeneca, and consulting fees from Alexion\/ AstraZeneca, Day One Biotherapeutic, Ipsen, Novartis, SpringWorks\/Merck and Trogenix. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}